definiens: shall mean any issued patent or or any patent application owned by MSSM, listed in this subclause1(i)-(xiii ), together with any continuations in whole or in part, divisional, or substitute patents, any reissues or re - examinations of any such application or patents, any foreign counterparts of any such application or patents, and anyextension of the term of any such patent in the Field . The issued patents and patent applications referred to in thepreceding sentence are : i ) U.S. Pat . No . 6,274,597 — ii ) U.S. Pat . No . 6,583,158 ( continuation - in - part)- iii ) U.S. Pat . No . 6,744,135 ( continuation of the ‘ 597 patent)- iv ) U.S. Pat . No . 6,599,919 ( continuation of the ‘ 053 CIP application)- v ) U.S. Pat . No . 6,589,964 ( continuation of the ‘ 919 patent)- vi ) U.S. Pat . No . 6,916,829 ( continuation of the ‘ 919 patent)- vii ) U.S. Pat . No . 10/868,133 ( continuation of ‘ 135 patent)- viii ) Allowed U.S. Pat . Applic . No . 10/989,258 ( continuation of the ‘ 829 patent)- ix ) U.S. Pat . Applic . No . 11/264,672 ( continuation of the ‘ 258 application)-”Method for Enhancing Mutant ProteinActivity ” [ * * * ] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HASBEEN REQUESTED . ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES ANDEXCHANGE COMMISSION PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIESEXCHANGE ACT OF 1934, AS AMENDED 4 x ) U.S. Pat . Applic . No . 10/377,179- xi ) U.S. Pat . Applic . No . 10/781,356- xii ) U.S. Pat . Applic . No . 11/317,404- j